Sydney Lupkin

Charles Maines, a Moscow-based correspondent, discusses the U.S.-brokered peace deal for Ukraine, detailing contentious points like territory and troop limits. Stephen Fowler analyzes Marjorie Taylor Greene's resignation and its implications for GOP dynamics. Sydney Lupkin introduces new oral semaglutide obesity pills, explaining their unique absorption method and potential accessibility issues. Andrew Limbong shares exciting recommendations from NPR's Books We Love roundup, highlighting both gripping fiction and insightful nonfiction gems.

Sydney Lupkin, an NPR pharmaceuticals correspondent, delves into the often-overlooked world of women's hair loss with Allison Richards, who shares her journey with androgenetic alopecia. They discuss how common hair loss is among women and tackle the myths surrounding popular remedies like rosemary oil. Sydney highlights the significance of getting accurate diagnoses and the evolving role of telehealth in hair care. Allison also reflects on the dual nature of social media, revealing both the pressure to conform to beauty standards and the comfort found in community support.

Sydney Lupkin, an NPR Pharmaceuticals correspondent, dives into the buzz surrounding GLP-1 drugs like Ozempic and their potential pill formulations. She explains how these injectables have transformed weight loss therapies and shares insights on the development of oral versions, including Novo Nordisk's semaglutide pill and Eli Lilly's innovative Orforglipron. These new options promise improved access and lower costs, revolutionizing treatment for many. Lupkin also discusses patient preferences for pills over injections, highlighting the evolving landscape of diabetes care.

Sydney Lupkin, NPR's pharmaceuticals correspondent, breaks down a pivotal moment in U.S. healthcare policy. The government can now negotiate Medicare drug prices, a move decades in the making. She discusses the ten drugs under negotiation and what that means for seniors facing high costs. The challenges ahead include pharmaceutical lobbying and potential legal battles. Furthermore, Lupkin analyzes how this initiative could sway upcoming elections and reshape public opinion on healthcare affordability. It's an enlightening conversation on a crucial topic.

Sydney Lupkin, NPR's pharmaceuticals correspondent, dives into the world of accelerated drug approvals and the promises drugmakers must keep. She discusses the urgent history behind this FDA process, particularly during the AIDS crisis. Lupkin reveals concerning stories, including tragic outcomes linked to insufficiently validated drugs. The conversation sheds light on the challenges of ensuring ongoing accountability and the dire need for thorough follow-up studies to protect patient safety and trust in the pharmaceutical system.